Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis.

Antimicrobial agents and chemotherapy, Volume: 65, Issue: 11
October 18, 2021
Santosh Wagh S, Chetan Rathi C, Pradeep B Lukka PB, Keyur Parmar K, Zaid Temrikar Z, Jiuyu Liu J, Michael S Scherman MS, Richard E Lee RE, Gregory T Robertson GT, Anne J Lenaerts AJ, Bernd Meibohm B

Despite decades of research, tuberculosis remains a leading cause of death from a single infectious agent. Spectinamides are a promising novel class of antituberculosis agents, and the lead spectinamide 1810 has demonstrated excellent efficacy, safety, and drug-like properties in numerous and assessments in mouse models of tuberculosis. In the current dose ranging and dose fractionation study, we used 29 different combinations of dose level and dosing frequency to characterize the exposure-response relationship for spectinamide 1810 in a mouse model of Mycobacterium tuberculosis infection and in healthy animals. The obtained data on 1810 plasma concentrations and counts of CFU in lungs were analyzed using a population pharmacokinetic/pharmacodynamic (PK/PD) approach as well as classical anti-infective PK/PD indices. The analysis results indicate that there was no difference in the PK of 1810 in infected compared to healthy, uninfected animals. The PK/PD index analysis showed that bacterial killing of 1810 in mice was best predicted by the ratio of maximum free drug concentration to MIC (/MIC) and the ratio of the area under the free concentration-time curve to the MIC (AUC/MIC) rather than the cumulative percentage of time that the free drug concentration is above the MIC (%). A novel PK/PD model with consideration of postantibiotic effect could adequately describe the exposure-response relationship for 1810 and supports the notion that the observed postantibiotic effect of this spectinamide also translates to the situation in mice. The obtained results and pharmacometric model for the exposure-response relationship of 1810 provide a rational basis for dose selection in future efficacy studies of this compound against M. tuberculosis.

Courtesy of the U.S. National Library of Medicine